Scientific reports · 2017
Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lee Mei-Hsuan, Huang Chung-Feng, Lai Hsueh-Chou, Lin Chun-Yen, Dai Chia-Yen, Liu Chun-Jen, Wang Jing-Houng, Huang Jee-Fu, Su Wen-Pang, Yang Hung-Chih, Kee Kwong-Ming, Yeh Ming-Lun, Chuang Po-Heng, Hsu Shih-Jer, Huang Ching-I, Kao Jung-Ta, Chen Chieh-Chang, Chen Sheng-Hung, Jeng Wen-Juei, Yang Hwai-I, Yuan Yong, Lu Sheng-Nan, Sheen I-Shyan, Liu Chen-Hua, Peng Cheng-Yuan, Kao Jia-Horng, Yu Ming-Lung, Chuang Wan-Long, Chen Chien-Jen
Аннотация
This follow-up study enrolled chronic hepatitis C patients to evaluate the treatment efficacy and to identify post-treatment seromarkers associated with risk of hepatocellular carcinoma (HCC) among patients with a sustained virological response (SVR) or nonsustained virological response (NSVR). A total of 4639 patients who received pegylated interferon and ribavirin during 2004-2013 were followed until December 2014. HCC was confirmed through health examinations and data linkage with a national database. A total of 233 HCC cases were reported after 26,163 person-years of follow-up, indicating an incidence of 8.9 per 1000 person-years: 6.9 for SVR and 21.6 for NSVR per 1000 person-years. The associated risk of HCC in patients with SVR was 0.37 (0.22-0.63) for those without cirrhosis and 0.54 (0.31-0.92) for those with cirrhosis compared with their respective counterparts with NSVR. Among patients with SVR, advanced age, male gender, cirrhosis, decreased platelet count, and increased aspartate aminotransferase and α-fetoprotein levels were associated with HCC (p < 0.001). The treatment of chronic hepatitis C patients before they developed cirrhosis showed a higher efficacy than did the treatment of those who had already developed cirrhosis. Patients with SVR may still have a risk of HCC and need to be regularly monitored.